CYP2C9 Genetic Polymorphisms and Warfarin

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 2, 2004, Pages 149-154

  Redman, Andrea R ^a   Dickmann, Leslie J ^b   Kidd, Robert S ^c   Goldstein, Joyce A ^d   Ritchie, Denise M ^e   Hon, Yuen Yi ^a  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SHENANDOAH UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Cytochrome P 450 enzyme system; Genotype; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CYP2C9 GENE; DRUG METABOLISM; GENE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; LOW DRUG DOSE; MALE; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AFRICAN AMERICANS; AGED; ARYL HYDROCARBON HYDROXYLASES; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; STEREOISOMERISM; WARFARIN;

EID: 1842863167     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000205     Document Type: Article

References (25)

1. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. CHEST 2001;119:8S.
2. Chan E, McLachlan AJ, Pegg M, et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994;37:563.
3. Henne KR, Gaedigk A, Gupta G, et al. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B 1998;710:143.
4. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67.
5. Miners JO, Birkett DJ. Cytochrome P450 2C9: An enzyme of major importance in human drug metabolism. Br J Clinical Pharmacol 1998;45:525.
6. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in vitro and human data. Pharmacogenetics 2002;12:251.
7. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519.
8. Rettie AE, Haining RL, Bajpai M, et al. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 1999;35:253.
9. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361.
10. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39.
11. Yamazaki H, Inoue K, Shimada T. Roles of two allelic variants (Arg 144Cys and Ile359Leu) of cytochrome P450 2C9 in the oxidiation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 1998;28:103.
12. Yamazaki H, Inoue K, Chiba K, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998;56:243.
13. Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene. Pharmacogenetics 2000;10:85.
14. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382.
15. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001;11:803.
16. Goldstein JA. Polymorphisms in the human CYP2C subfamily. Drug Metab Rev 2002;34:5.
17. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphisms of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5:389.
18. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717.
19. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690.
20. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polyrnorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702.
21. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard Multimedia; 2003. Updated August 26, 2003.
22. MICROMEDEX [database online]. Greenwood Village, CO: Thomson MICROMEDEX; 2003. Updated June 30, 2003.
23. Bussey HI. How to monitor the dosage of warfarin. Heart Dis Stroke 1993:388.
24. Oertel LB. Managing maintenance therapy. In: Ansell J, Oertel L, Wittkowsky A, eds. Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. Maryland: Aspen; 1997:4B3:1.
25. Ansell JE, Buttaro ML, Thomas OV, et al. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother 1997;31:604.